看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
) r! ]9 `' v0 i0 f4 G7 j/ g9 y' A
, I8 Q2 A1 x; [/ w3 m5 {
Currently available feasibility data for possible combination strategies. 4 Z. N" x! Q5 D0 [' [' {2 w1 E
————————————————————————————————+ j+ M5 o" }3 d- X0 K/ o& F
Combination Feasibility according to preliminary data
1 f+ D9 \0 L$ z9 @5 G: x——————————————————————————————————
: u& z% `4 j5 H/ D& i! x: s) Y! EBevacizumab + sorafenib Yes, reduced dose
, }$ A7 b. ]) k4 U5 R$ w0 l7 B* @Bevacizumab + sunitinib† No
9 w8 i, i5 D& j$ e/ [ y& ~Bevacizumab + temsirolimus Yes 6 [ y# u+ b. I0 K) G2 M( j ~" u
Bevacizumab + everolimus Yes
* E) {1 r/ l \# K- dSorafenib + sunitinib ? $ X# I, S6 X2 X. _0 ` p' N, W
Sorafenib + temsirolimus Yes, reduced dose
9 X4 `- \: [+ X* p' `Sorafenib + everolimus Yes, reduced dose * `; P5 T h9 q" P7 k, ~0 u& z
Sunitinib + temsirolimus† No
) W+ U7 A# Q8 B6 TSunitinib + everolimus ?
2 Y5 G8 j% q: T$ ?3 pTemsirolimus + everolimus ?
& }) T/ {; x; B7 p0 l7 S————————————————————6 e7 t1 o: H1 u9 N5 x' c
†Led to US FDA warning.
* g8 K6 L' g5 o?: As yet unattempted combination.
% t: q9 {% X D4 V: I$ w |